Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
It’s a simple idea that surprisingly, hasn’t been implemented or seriously studied and tested, until now: full integration of the most effective family planning services with […]
How do you reach the three million people who become ill with tuberculosis every year, but go undetected, suffering and dying needlessly, while infecting others? The […]
HIV vaccine development, combination prevention, antiretroviral treatment top agenda as briefing eyes progress against 2.3 million new infections
With the wait for a vaccine against HIV stretching back to when the virus was first identified 30 years ago, how do you measure progress? You […]
As global health leaders from around the world gather in Washington, D.C. this week for the fourth replenishment of the Global Fund to Fight AIDS Tuberculosis […]